Continuous Clopidogrel Dose Adjustment in Acute Coronary Syndrome Patients With High On-treatment Platelet Reactivity

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2014

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Clopidogrel dose adjustment

"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity \>18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if \>46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients \>70 years 150 mg)"

Trial Locations (1)

10000

University Hospital Centre Zagreb, Zagreb

All Listed Sponsors
collaborator

Clinical Hospital Centre Zagreb

OTHER

collaborator

Ministry of Science, Education and Sport, Republic of Croatia

OTHER_GOV

lead

University of Zagreb

OTHER

NCT02096419 - Continuous Clopidogrel Dose Adjustment in Acute Coronary Syndrome Patients With High On-treatment Platelet Reactivity | Biotech Hunter | Biotech Hunter